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The problem of racemization in drug discovery and tools to predict it. 
 
Abstract 
Introduction 
Racemization has long been an ignored risk in drug development, probably because of 
a lack of convenient access to good tools for its detection and an absence of methods to 
predict racemization risk. As a result, the potential effects of racemization have been 
systematically underestimated. 
 
Areas covered 
Herein, the potential effects of racemization are discussed through a review of drugs 
for which activity and side effects for both enantiomers are known. Subsequently, drugs 
known to racemize are discussed and we review methods to predict racemization risk. 
Application of a method quantitatively predicting racemization risk to databases of 
compounds from the medicinal chemistry literature shows that success in clinical trials 
is negatively correlated with racemization risk. 
 
Expert opinion 
It is envisioned that a quantitative method of predicting racemization risk will remove 
a blind spot from the drug development pipeline. Removal of the blind spot will make 
drug development more efficient and result in less late-stage attrition of the drug 
pipeline. 
 
Keywords 
Racemization; quantitative prediction; stability; enantiomers; risk; 
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1. Introduction 
 
It is generally accepted that enantiomers of chiral compounds can have very different 
effects in chiral environments. Patients are an intrinsically chiral environment, and in 
drug development we therefore distinguish the enantiomers of a drug as the eutomer 
(the good enantiomer) and the distomer (the unwanted enantiomer). It is considered 
desirable practice to administer chiral compounds as single enantiomers and to profile 
the properties of both enantiomers before regulatory approval. In fact, even drugs that 
are initially administered as the racemate (the 50:50 mixture of the two enantiomers) 
can be considered for a so-called “chiral switch”, i.e. development of a single-
enantiomer alternative. 
 
Racemization is the process whereby a single enantiomer is converted into a mixture of 
both enantiomers.  Thus, if a compound that tends to racemize is administered as a drug, 
the patient will over time very probably be exposed to both enantiomers even if the 
original preparation was a single enantiomer. Racemization is a particular concern to 
drug discovery because, as mentioned above, the two enantiomers are highly likely to 
have different biological properties, particularly in vivo.  A process related to 
racemization is that of enantiomerization, which refers to one enantiomer being 
stereoselectively converted into the other and which can also lead towards a mixture of 
the two enantiomers. 
 
The impact of chirality on drug discovery has been reviewed previously and here we 
focus primarily on work that includes specific studies of the process of racemization.  
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Relevant reviews include general surveys of chiral drugs, as well as those that describe 
the impact of chirality on toxicity and on synthesis.[1-5]  Some studies of racemization 
have also been reviewed elsewhere.[6, 7] In the context of dynamic kinetic resolution 
for the preparation of highly enantio-enriched materials, a rapid racemization is often 
desirable.[8] Where an enzyme is the chiral catalyst, racemization must occur in 
conditions that are compatible with the enzyme. These conditions are likely to be 
similar to those in biological systems in general, and therefore also to be relevant to 
drug discovery. 
 
In the following sections we first describe studies that illuminate the impact that 
racemization has on drug safety and efficacy.  This is followed by a description of 
studies that have investigated the process of racemization in biologically relevant 
conditions.  Methods to predict racemization are then described and applied to a set of 
approved drugs and clinical candidates. 
 
2. The problem of racemization. 
 
Although it is known and understood that the two enantiomers of a molecule must 
experience a different response to any chiral environment (such as a protein), this 
difference could be large or small.  If the difference were small then the divergent 
biological properties of enantiomers might be safely ignored in all but the most extreme 
cases and racemization would therefore be of little concern.  Understanding this 
difference between enantiomers is therefore critical to determining the importance of 
racemization.  There are many relevant reports, including some systematic surveys and 
many case studies, several of which we describe here.[9]  
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2.1 Case studies detailing the differences and similarities between the activity 
and safety of enantiomers of individual drugs. 
 
We first review the literature on drugs and drug candidates for which differences in 
activity for the two enantiomers are known. 
 
<<Figure 1 approximately here>> 
 
Compounds where the safety of the two enantiomers has been investigated are 
discussed first. One of the most well-known examples of a drug with dangerously 
different activity between the two enantiomers is thalidomide, 1.  The S-enantiomer is 
believed to be teratogenic.[10, 11] The pharmacokinetics of the two enantiomers also 
differ, with S-1 being eliminated faster than R-1 in humans.[12] However, S-1 is 
absorbed more quickly. S-Clopidogrel, 2, is an anti-platelet medication that is 
administered as a pro-drug.[13] It undergoes several key metabolic steps in vivo. While 
the R-enantiomer is inactive, at high doses it can cause convulsions. The harmful effects 
of the distomers of 27 drugs were summarized in a review from 2007.[14] At the most 
benign, the distomer is inactive but toxicity is noted for thalidomide (1), penicillamine 
(3), propranolol (4), vigabatrin (5), tramadol (6) and 2-[2,6-dioxopiperidine-3-yl]-
phthalimidine (7).[14] Levobupivacaine, R-8, is less cardiotoxic than racemic 
bupivacaine.[15] This reduced cardiotoxicity prompted a stereoselective synthesis to 
be developed that involved a resolution and so racemization was desired in order to 
permit the undesired enantiomer to be recycled into levobupivacaine.  High 
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temperatures (138 °C) and the addition of ethylene glycol to the aqueous system were 
found to promote almost complete racemization within 9 hours.  
 
The relative efficacy of the two enantiomers has also been investigated for several 
compounds. Cetirizine, 9, is an antihistamine by virtue of being a selective antagonist 
of the H1-receptor. It is sold as a racemate which raised the possibility that a chiral 
switch could see an improved single stereoisomer version (which was subsequently 
pursued).[16] A decision tree for making this choice was proposed based on the 
difference in pharmacokinetics and pharmacodynamics of the enantiomers and their 
comparison to those for the racemate.  Levocetirizine was found to have 2-fold higher 
apparent affinity for the H1-receptor than the racemate;[17] this presumably results 
from the concentration of levocetirizine accounting for half of the concentration of 
racemic cetirizine. The affinity of dextrocetirizine was 30-fold lower than for the 
racemate. The difference between the affinity of the two enantiomers is accounted for 
by the longer dissociation half-life of the levocetirizine. In trials in healthy volunteers, 
levocetirizine was as effective as the racemate but dextrocetirizine was less effective.  
Although the maximum effect for levocetirizine occurred at 6 hours after dosing, at 32 
hours the response to levocetirizine was statistically superior to that for the racemate.  
Low levels of metabolism were observed for both enantiomers but the volume of 
distribution was higher for the distomer, dextrocetirizine. It was suggested that this 
higher volume of distribution might make dextrocetirizine more likely to cause 
unwanted side-effects. The very comprehensive package of data for cetirizine was used 
to support a case for the use of single enantiomer levocetirizine and reflects the 
importance of understanding stereochemical detail for a candidate drug.  
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Adrenaline, 10, can be used to induce vasoconstriction at the site of injection of local 
anaesthetics and the L-form is 10 times more effective than the D-form.[18] Certain 
aromatase inhibitors, such as fadrozole, 11, have significantly different activities for 
each of the two enantiomers; S-fadrozole is most active for instance.[19]  
 
Other studies have investigated the pharmacokinetic properties of enantiomers. 
Ketoprofen, 12, is a non-steroidal anti-inflammatory and its delivery via a trans-dermal 
route has been considered.[20] When used orally, it is delivered as a racemate but 
stereoselective skin permeation might favour its use as a single enantiomer for this 
alternative delivery route. Studies showed the racemate to be higher melting than the 
individual enantiomers and x-ray diffraction patterns support the racemate having a 
different solid form than the individual enantiomers suggesting that the two 
enantiomers co-crystallize and are both present in the unit cell. When 0.05 M solutions 
of each of the enantiomers was applied to mouse skin, no difference in permeation was 
detected between enantiomers or racemate.  Further studies supported no 
stereoselectivity for skin permeability for ketoprofen.  
 
Ketorolac, 13, was investigated in a pharmacokinetic study in healthy volunteers.[21] 
Following intravenous injection, the concentration of the two enantiomers was 
monitored separately.  This showed that S-ketorolac is cleared more rapidly than the R 
enantiomer leading to higher exposure to R-ketorolac. 
 
2.2. Surveys 
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In addition to investigating the differences between properties of individual 
compounds, larger scale data analyses have also been performed to determine general 
trends. In one such survey, all of the compounds in AstraZeneca’s corporate database 
where each enantiomer had separately had a key biological property measured were 
identified.[22] These properties included lipophilicity, solubility, permeability, plasma 
protein binding, metabolism by microsomes, metabolism by hepatocyte cells, inhibition 
of certain cytochrome P450 enzymes, block of the hERG cardiac potassium channel 
and in vivo pharmacokinetic parameters.  Most of the properties (apart from logD) 
required logarithmic transformation to put them onto a linear scale. A statistical 
analysis of the difference in measured properties between enantiomers was compared 
to the difference found when measurements were repeated on the same compound.  This 
analysis permitted identification of properties where there is a difference between 
enantiomers that exceeds the uncertainty in the measurement.  In Figure 2A, any 
property that has a bar adjacent to it is one where enantiomers are found to differ.  
Inhibition of the cytochrome P450 (CYP) enzymes and in vivo pharmacokinetic 
parameters (volume of distribution and clearance) are prominent examples.  
Metabolism, as measured in either hepatocyte cells or microsomal preparations, shows 
a difference between enantiomers as does binding to plasma proteins and block of the 
hERG channel.  As expected, solubility and logD do not show a difference between 
enantiomers.  Surprisingly, in assays to assess permeability through cells or efflux (an 
active process mediated by membrane-bound proteins) no significant difference 
between enantiomers was found. 
 
<<Figure 2 approximately here>> 
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A similar analysis by researchers at Novartis compared the difference between 
enantiomers to that between repeat measurements.[23] The distribution of both was 
compared using the Kolmogorov-Smirnov test and the properties examined were 
solubility, permeability, CYP inhibition, metabolism in rat microsomes, hERG block 
and biochemical activity in a randomly selected primary potency screen (isocitrate 
dehydrogenase, IDH). In addition to testing for whether the distributions are distinct, 
the authors also assessed whether the difference was likely to be of practical relevance. 
A p-value assessed whether the distributions are statistically distinct and the authors 
quantify the difference as the D-value. Figure 2B shows the parameters that achieve 
this difference and the corresponding D-values are shown as solid bars. Parameters 
affected by chirality include inhibition of IDH, microsomal metabolism and hERG 
block.  They then did a further test to determine whether the difference is likely of 
practical relevance (assumed to be the case if the D-value, plotted in Figure 2B, was 
above 0.1).  On these grounds they suggest that, although in agreement with the 
AstraZeneca findings for hERG block on purely statistical grounds, the difference in 
hERG block by different enantiomers is unlikely to be of practical importance.  When 
a compound blocks the hERG channel, it is possible that this can lead to death of an 
otherwise healthy patient.[24] We are therefore unsure whether to accept these authors’ 
assessment of relevance. More intriguing is inhibition of CYP3A4. For CYP3A4, the 
AstraZeneca analysis supports a small but significant difference, whereas the Novartis 
data suggests a difference that is not significant but which might be large enough to be 
important.  In both cases, CYP3A4 is of borderline significance and so it may not be 
surprising that the final classifications differ. Both hERG and CYP 3A4 are often 
characterized as being flexible proteins with large binding cavities and it may be that 
this leads to weak differentiation of enantiomers.[25, 26] 
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3) Measurements of rates of racemization. 
 
Having confirmed the potential for significantly different effects of enantiomers when 
used as drugs, both for individual compounds and in general, we now review reports 
where racemization has been studied. 
 
3.1.Generalized racemization mechanisms 
 
In general, there are two dominant mechanisms by which compounds can racemize in 
aqueous solutions. These mechanisms are deprotonation of a carbon acid under basic 
conditions and dehydration of an alcohol under acidic conditions (Figure 3A and B). 
 
Other mechanisms do occur but are far less general. An example of an alternative 
mechanism is provided by the racemization of allantoin which racemizes via both the 
usual deprotonation and via an intramolecular nucleophilic attack (Figure 3C).[27] 
 
 
3.2. Examples of racemizing drugs 
 
Studies of the racemization of several drugs have been published and we now 
summarize these reports. 
 
<<Figure 3 approximately here>> 
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Initial studies showed that thalidomide 1 racemizes in phosphate buffer (half life of 260 
– 290 minutes) and does so even more rapidly in citrated human plasma (half life 8 – 
12 minutes) and that a similar half life is found for defatted human serum albumin 
(HSA) in phosphate buffer.  Presumably racemization of 1 proceeds via the general-
base-mediated process shown in Figure 3A. Rat liver microsomes did not promote the 
racemization.[28] Such studies were extended to show that HSA is mildly 
stereoselective and promotes the racemization of S-1 slightly more than it does R-1.[11] 
The rate of racemization in phosphate buffer was related to the buffer strength. The 
ability of various amino acids to catalyse racemization was also investigated and 
showed that the basic amino acids lysine and arginine were more catalytically active 
than acidic or neutral amino acids.  It was noted that albumin incorporates many basic 
amino acids, including some in the known binding sites and some of these basic groups 
presumably facilitate the observed racemization.  This catalysis is fairly non-specific 
but is reduced in vivo when many of albumin’s binding sites are occupied by molecules 
such as fatty acids and bilirubin. Since the compound readily racemizes in vivo, it is 
now known that the tragic consequences of this compound’s use during the 1950s could 
not have been avoided by providing patients with a single enantiomer.[10, 11] 
 
Studies of the racemization of 2 in vitro needed to include hepatocytes, because 
metabolism and the formation of conjugates are likely to be important in any 
racemization in vivo.[13] In vivo studies were also performed and suggested that the 
acid is the predominant circulating metabolite and that 4 – 8 % of the acid is the R 
enantiomer. In vitro, the half life of racemization was found to be in the range 3.5 to 
8.5 weeks with a dependency on the buffer and the methanol concentration (methanol 
was required to improve solubility).  Complementary studies investigated isotope 
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exchange in D2O.  Even with the hepatocytes present, less than 2 % inversion was 
detected and so no satisfactory explanation was provided for the level of racemization 
measured in vivo. We have subsequently also studied racemization of 2 and found that 
racemization of 2 in vitro is likely to appear much slower than it is in reality because 
of the very poor solubility of 2 limiting the amount of free 2 in solution. 
 
The discussion of the racemization of 27 drugs from 2007 mentioned above reviewed 
several studies of racemization, including the possibility of racemization being 
mediated by degradation and bioconjugation (such as the formation of S-CoA 
thioesters).[14] 
 
The requirement for extreme conditions for racemization of levobucaine (R-8) in its 
dynamic kinetic resolution (vide supra) make racemization unlikely to occur in vivo. 
 
In trials in healthy volunteers, using radiolabelled levocetirizine R-9, it was found that 
the total concentration of cetirizine was equivalent to the concentration of levocetirizine 
and no dextrocetirizine was found in urine. Both of these observations support the 
conclusion that there is no in vivo racemization, in agreement with observations in pH 
7.4 buffer.[16]  
 
Considering the significant difference in activity between L- and R-adrenaline, 
racemization would significantly reduce activity. Studies of a range of products 
including those mixed with anaesthetics found racemization of adrenaline (10) to be 
slow.[18] 
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To investigate the racemization of fadrozole (11), a set of N-substituted imidazoles 
were investigated.[19] It was found that two of the compounds racemize measurably in 
aqueous buffer at pH 7.4 and pH 9.6 with longer half lives at pH 7.4 supporting a 
general-base-catalysed process (Figure 3A).  Studies in bovine serum albumin 
suggested that this medium had little effect. 
 
In the studies where ketoprofen (12) was applied to mouse skin, no racemization was 
detected.[20] 
 
Ketorolac (13) is a non-steroidal anti-inflammatory agent sold as a racemic mixture.  
Its racemization is found to be pH dependent and to be slowest at intermediate pHs (3.0 
– 7.5).[29, 30]  A mechanism for racemization involving deprotonation of the already 
anionic carboxylate at high pH and protonation of the neutral acid at low pH is proposed 
(Figure 3D).  
 
Litronesib, 14a, is an investigational compound that inhibits Eg5 and has been 
investigated as a treatment for several types of malignancy.[31] An unexpected loss of 
chiral integrity was observed upon storage of this compound. The chiral centre in this 
case is fully substituted and so the racemization was surprising.  Studies in tartrate 
solutions across a pH range from 2.1 to 8.2 and using other buffers suggested that pH 
is the key factor rather than buffer identity.  Extensive studies led to the proposal of the 
ylid-mediated path shown in Figure 3E.  The analogues 14b and 14c helped elucidate 
the mechanism; 14b is racemized about twice as fast and 14c three times as slowly as 
14a, consistent with the ylid structure shown. 
 
13 
 
Agonists of the 2 adrenoceptor are often chiral benzyl alcohols with activity usually 
resting predominantly with the R-enantiomer.[32] An example of such a molecule is 
meluadrine, 15. Studies of 15 led to the conclusion that across the pH range the 
mechanism of racemization involves elimination of OH followed by rehydration.  
Meanwhile, the details concerning the protonation of the base and alcohol vary (Figure 
3F). Arrhenius plots at various temperatures suggested an activation energy in the range 
95 – 115 kJ/mol.  Other studies of the stability of chiral benzyl alcohols have described 
in detail the process by which the leaving alcohol must leave the solvent cage and join 
bulk water to permit access to the planar carbocation intermediate that would be 
required for racemization.[33] 
 
A purely computational study investigated the possibility of inversion at sulfur in the 
proton pump inhibitor esomeprazole (16).[34] A mechanism in which the pyramidal 
sulfur becomes planar was studied and the barrier to inversion computed to be 
prohibitively high (180 kJ/mol) suggesting that very high temperatures would be 
required for this to operate. 
 
An innovative method using three different regions in a flow set up permitted separation 
of enantiomers, racemization and analysis within a closed system.[35]  This method 
was used to study 17. The mechanism of racemization was proposed to involve a ring 
opening to an intermediate that also provided access to a hydrolysis product (Figure 
3G). We propose (given pKa considerations) an alternative intermediate, which 
proceeds via a cleavage in which the sulfonamide acts as leaving group. 
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The racemization of mandelic acid (18) was found to proceed faster than the rate of 
deuterium incorporation under acidic conditions.[36] It is proposed that under these 
conditions, racemization (or possibly enantiomerization) occurs via protonation of the 
hydroxyl with displacement by water.  By contrast, in neutral and basic conditions, the 
rates are the same and the racemization proceeds via the general-base-catalysed process 
involving the enol(ate) (Figure 3H). 
 
Amfepramone (19) is a stimulant that can be used as an appetite suppressant and is 
usually used as a racemate.[37] The rate of racemization was studied as buffer strength, 
ionic strength, temperature and drug concentration were varied.  The dependence on 
pH and on buffer strength revealed non-linear relationships. Cyclodextrin additives 
were also investigated for their ability to suppress racemization but showed mixed 
results with most examples actually promoting racemization while only a small number 
were protective.  In human plasma, the half life for racemization was measured to be 
23 – 25 minutes but this is much lower than the known in vivo half life following oral 
dosing of 1.5 to 2 hours. Studies in phosphate buffers at a range of pHs and buffer 
strengths support a general-base-catalyzed reaction (Figure 3A) for 19 and the 
analogous primary amine. 
 
As part of a search for safe versions of thalidomide, the rate of enantiomerization of 7 
and of lenalidomide 20 were measured alongside those for 1 (thalidomide) in 50 mM 
phosphate buffer at pH 8.[38] Although it is likely that these compounds racemize, like 
thalidomide, the use of dynamic electrokinetic chromatography means that only the 
enantiomerization can be observed. By investigating the variation with temperature, the 
activation parameters were derived and revealed that at 298 K the Gibbs free energy 
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barrier (ΔG‡o) for enantiomerization of 1 is 101.7 kJ/mol (with ΔH‡o 99.0 kJ/mol), for 
7 the barrier is 96.8 kJ/mol (with ΔH‡o 46.1 kJ/mol) and for 20 the barrier is 91.5 kJ/mol 
(with ΔH‡o 62.4 kJ/mol). This suggests that these other examples are more likely to 
racemize than thalidomide itself. 
 
The half life for racemization of 21 was studied in a range of media.[39] A surprising 
dependence on pH was observed in which the rate was fastest at pH 6, slowest at pH 9 
and intermediate at pHs 4 and 7. In all cases, the half life was less than 2 hours. Rapid 
racemization (half life of a few minutes) was also measured in dog plasma. Although 
no mechanistic proposals are made, it seems realistic to imagine that this compound 
could racemize through an acid-catalysed ring-opening ring-closing mechanism or 
through a base-catalysed process (as for Figure 3A) and this would reasonably lead to 
a complicated dependence on pH. 
 
 
3.3. Racemization of model drugs 
 
A significant expansion of the dataset of aqueous racemization rates has been described 
in recent publications.[6, 40-42] The rates of racemization of 28 different model 
compounds racemizing by the base-catalysed pathway were reported.  These included 
a series of compounds with chiral centres bearing an N-linked amide and an aromatic 
ring with either a C-linked amide or a C-linked ester as the third substituent (22 and 
23).  A further set included hydantoins (24) and thiohydantoins (25) (some hydantions 
had been studied previously).[43] The rate of racemization in phosphate buffer was 
studied and the second-order rate constant for the general-base-catalysed racemization 
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of each compound was obtained.  These were measured using a range of experimental 
techniques, including circular dichroism spectroscopy and monitoring deuteration in 
D2O using 1H NMR spectroscopy.  The second-order rate constants were found to span 
over 4 orders of magnitude and to bracket rates likely to be of biological relevance. 
 
4. Tools to predict racemization. 
 
In a thorough review of stereochemistry and racemization, Testa provided a table that 
defines the types of group that can either increase or decrease configurational stability 
(Table 1).[9, 44] He suggested that stereochemical instability requires the presence of 
at least one of the groups that decrease stability and the absence of any of the groups 
that increase stability.  This provides a rule of thumb that can easily be kept in mind by 
chemists designing new molecules but has a narrow scope and is acknowledged to be 
based on limited evidence for certain groups.   
 
<<Table 1 approximately here>> 
 
This approach was updated in 2018 with two computational approaches paired with 
two experimental approaches.[6] In all cases, any stereogenic carbon that has a proton 
attached to it can be analysed with an assumption that the most likely mechanism of 
racemization for such compounds will be general-base-catalysed deprotonation to give 
an anionic intermediate (Figure 3A). The computational methods both rely on 
predicting the stability of this anion and correlating this with measured rate constants 
(both those reported in the same paper and those in the literature that were measured 
under suitable conditions). The first and most readily applicable of the computational 
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methods is based on group contributions.  These are shown in Table 2.  The contribution 
of all of the groups is added together.  There is a correction if two or more of the groups 
stabilize the anion via delocalisation; this cross-conjugation correction is +15.0 
kcal/mol.  The resulting value () can be used to predict the second-order rate constant 
for racemization via general-base-mediated reaction (kgb) using the equation: 
 
log(kgb) = -0.11 - 9.81 
 
There is an interesting subset of cases (including compounds like 21, 24 and 25) where 
the stereogenic centre is in a ring and the reaction can proceed through an anion that is 
formally aromatic.  In such cases, a modified equation is applied: 
 
log(kgb) = -0.26 - 16.95 
 
An alternative view is to determine a cut-off value of  where the corresponding rate 
constant indicates that racemization is likely to be of biological relevance.  Comparing 
values measured in different media suggests that blood might be similar in terms of 
general-base capacity to phosphate buffer with a concentration of 0.15 M.[12] This 
leads to the suggestion that if an amount of racemization in a given time period that is 
thought acceptable can be determined then a threshold for acceptability can be defined.  
For instance, if 10% racemization within 24 hours were deemed the acceptable limit 
then any compound with a sum of contributions below -44 kcal/mol should be 
considered at risk. 
 
<<Table 2 approximately here>> 
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The group contribution approach has the power of being applicable very rapidly via 
implementation as a computational algorithm.  It is limited whenever there is cross-talk 
between the substituents (as in the cross-conjugation correction or the aromatic anion 
intermediates).  In such cases, a quantum mechanical approach can help.  It was shown 
that if the deprotonation energy is computed at the B3LYP/6-31+G** level (including 
solvation via the PCM protocol) that these energies also correlate with log(kgb).[45-48] 
The deprotonation energies are computed relative to methane to give a value styled 
∆∆G.  With this treatment kgb is obtained using:  
 
log(kgb) = -0.20∆∆G – 14.28 
 
This quantum mechanical method tends to give values in better agreement with 
experiment than the more general group-contribution-based method.  Applying the 
same approach to defining a threshold as described above yields a value of -45 
kcal/mol; any compound with a value of ∆∆G below this should be considered at risk 
of racemizing.  
 
Finally, experimental studies might be required to confirm a prediction or when the 
computational methods do not provide consistent predictions.  Following racemization 
by deuterium in deuterated buffers can use 1H NMR or mass spectrometry.  Care must 
be taken to correct for any other side-reactions (typically hydrolyses) and to investigate 
the influence of buffer concentration.  Alternatively, the reaction can be followed 
directly by circular dichroism. 
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5. Application of the predictive tool to drugs and clinical candidates. 
 
The European Bioinformatics Institute hosts the ChEMBL database and one of the 
subsets that they curate is described as “Drugs” including “Approved Drugs” up to 
March 2018.[49]  In addition, the set includes compounds that are under clinical 
investigation.  Compounds are annotated according to the most advanced clinical phase 
they have reached to date.  These are in the range 0 to 4, where 0 is pre-clinical and 4 
is approved.  Those compounds that have received at least one approval are annotated 
with the year of this first approval. They also annotate those compounds that are 
approved and subsequently withdrawn.  We have applied the group contribution 
method described above to assess the racemization liabilities that are present in this set 
of compounds.   
 
5.1.An overview of racemization risk in drugs and drug candidates 
 
We have identified all those compounds that have a single stereogenic carbon atom in 
them and which are computed to racemize to at least 10% within 24 hours.  In the first 
place, the percentage of all of the compounds in each of the clinical phases that these 
represent has been computed.  This is shown in Figure 4A and shows a very clear trend; 
there are proportionately fewer racemizing compounds as the clinical stages progress.  
This suggests that compounds that racemize are less likely to succeed in each clinical 
phase than compounds that do not racemize.  This is an interesting countervailing trend 
to one published previously which shows compounds that include at least one 
stereocenter are more likely to succeed in the clinic.[50] Racemizing compounds 
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therefore appear to be a particular liability in the clinic by decreasing the chance of 
success despite necessarily including a chiral center.  
 
<<Figure 4 approximately here>> 
 
It is worth noting that among compounds that have made it as far as approval, we find 
that 1.4 % are likely to racemize which is a higher proportion than is found in all of the 
clinical phases. The approved compounds have therefore been examined in more detail. 
The approved compounds in this set are made up of many different types of molecules 
(Figure 4B), amongst which the largest two groups are synthetic small molecules (1643 
compounds) and natural product derived molecules (547 compounds).  These are also 
the only two groups that include compounds that are computed to racemize (although 
it should be noted that stereochemical scrambling of one center in compounds with 
several stereogenic centers is predicted to occur in some of the other categories of 
compound).  There is an interesting divergence between the nature of the natural 
products and the synthetic small molecules in terms of their stereochemical makeup.  
Natural product derived drugs (Figure 4B bottom right) are overwhelmingly likely to 
be single stereoisomers (470) as compared to being achiral (27) or racemates (40). By 
contrast, for synthetic small molecules (Figure 4B bottom left), the largest group of 
compounds are achiral (820), followed by racemates (388) and then single 
stereoisomers (339).   
 
In the whole set of approved compounds, we predict that 37 are likely to racemize.  Of 
these only one (Valacyclovir) is from the natural product derived drugs, the remaining 
36 are synthetic small molecules.  It is unsurprising that 28 of these 37 compounds are 
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provided as racemic mixtures; this observation confirms that for these compounds 
racemization in vivo is sufficiently fast to make the use of a single enantiomer pointless.   
 
Among all of the drugs to have achieved approval, 149 (5.5 %) have subsequently been 
annotated as withdrawn.  Although the set of compounds is too small for the difference 
to be assessed as significant, 3 of the 37 (8.1 %) compounds that are predicted to 
racemize are annotated as withdrawn . 
 
The 9 compounds that are single stereoisomers but which are predicted to racemize are 
examined in more detail in the following paragraphs. 
 
5.2. Compounds predicted at risk of racemization distributed as a single 
enantiomer 
 
The compounds sold as single isomers but predicted to racemize are cycloserine (26), 
bentiromide (27), valacyclovir (28), ropivacaine (29), clopidogrel (2), brinzolamide 
(30), levobupivacaine (8), levocetirizine (9) and safinamide (31).  Two of these nine 
compounds (27 and 8) are annotated as discontinued (as distinct from withdrawn).  Two 
(2 and 28) are prodrugs for which the active drug is either achiral (28) or much less 
likely to racemize (2, as discussed above).   
 
The remaining five compounds are surveyed in more detail. Compound 26 is an 
inhibitor of alanine racemase, an enzyme that provides the D-Alanine required for cell 
wall biosynthesis.[51] It is likely that its ability to racemize is not a problem in this 
context. Compound 29 is a local anaesthetic that can be administered intravenously and 
22 
 
the single isomer version was promoted as providing reduced toxicity and improved 
efficacy.[52] In this case, studies of 29 in a range of species suggest that there is no 
racemization in vivo.[53] Compound 30 inhibits carbonic anhydrase and is used 
intraocularly via topical application and hence is likely to be protected from the 
racemizing medium of the plasma.[54] Antihistamine 9 had its in vivo racemization 
studied as described above.  It is likely that the steric bulk of the three rings (two phenyl 
and one piperazine) that must become co-planar inhibits racemization in this case. 
Whereas such effects can be reproduced reasonably well by quantum mechanical 
calculations, the group-contribution approach that we have used here does not account 
for the effects of steric hindrance. Finally, 31 is a relatively recently approved treatment 
for Parkinson’s disease that is used in tablet form for oral administration and for which 
the two stereoisomers show different profiles but rates of racemization have not been 
reported.[55] 
 
There is a temporal component to the drug approvals but not all of the compounds have 
had their approval data added to the database.  Of the compounds predicted to racemize, 
the largest number was approved in the 1990s (Figure 4C).  It was in 1992 that the US 
Food and Drug Administration (FDA) changed their guidance with regards to 
stereoisomers and required assessment of racemization rate and of the properties of the 
individual enantiomers.[56] There is no clear trend for changes either in the number of 
compounds that are likely to racemize being approved or in whether they are approved 
as single stereoisomers or racemates. The earlier period featured fewer single 
stereoisomers that are likely to racemize being approved, probably because of a reliance 
on configurationally stable natural product derivatives. Following the change in FDA 
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guidance in 1992, the number and proportion of compounds computed to be likely to 
racemize that were approved has decreased. 
 
6. Conclusions 
This review explores the merit of fast quantitative predictions of racemization risk in 
drug development. We show that racemization risk negatively affects a drug 
candidate’s chance to pass through clinical trials and that ignoring racemization risk 
therefore introduces an unnecessary risk in the drug development pipeline. 
 
7. Expert opinion.  
 
The two enantiomers of a molecule can have quite different biological properties. In 
particular, the primary potency, pharmacokinetic parameters and certain types of 
toxicity are likely to be different. This ensures that understanding the properties of the 
two enantiomers will be important in drug discovery and that the process of 
racemization will often be undesirable.  
 
7.1. Comparison with the status quo 
Racemization of drug-like compounds usually proceeds via a mechanism that can be 
easily understood by chemists.  The most common such mechanism is that of general-
base-catalysis via an intermediate, if transient, anion.  Ideas of delocalisation, electron-
withdrawing groups and steric effects permit the ready post-rationalisation of the 
occurrence of racemization (either in vivo or during the synthesis of chiral molecules).  
Unfortunately, the ease with which the past is understood has not yet been translated 
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into a ready ability to predict which compounds are likely to racemize in vivo. The 
status quo thus represents a considerable weakness in drug development. 
  
New computational and experimental tools transform this situation.  We advocate the 
use of three different methods in a tiered approach.  A simple group contribution 
method permits the prediction of rates of racemization with minimal computational 
cost.  For molecules of particular interest, or where there is uncertainty about the 
prediction, a quantum mechanical calculation can be performed.  Both of these methods 
rely on a close correlation between the stabilisation of the anionic intermediate and the 
rate of general-base-catalysed racemization. Finally, experimental approaches can be 
used where isotope exchange is followed by mass spectrometry or racemization by 
circular dichroism spectroscopy. This three-tiered quantitative approach is considerably 
more robust than the alternative descriptive approaches. Moreover, the fact that the 
group-contribution approach is conveniently automated through the use of SMILES 
descriptors makes it applicable to large databases of compounds, allowing efficient 
identification of racemization risk. 
 
7.2.Racemization risk in the current drugs and in the pipeline 
Application of the group contribution method to a database of marketed drugs reveals 
that compounds that racemize are less likely than other compounds to proceed from 
one stage of clinical testing to another, and this is despite the fact that compounds that 
contain a stereogenic center are generally more likely to succeed. Very few compounds 
that are predicted to racemize have been approved and those that have are 
predominantly prescribed as racemic mixtures.  Our analysis thus suggests that 
compounds at risk of racemization fare worse than typical chiral compounds. 
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Quantitative prediction of racemization risk will allow early identification of 
compounds at risk, providing an opportunity to avoid significant costs associated with 
compounds that fail in clinical trials. Quantitative prediction of racemization risk 
therefore facilitates drug discovery and reduces attrition. 
 
7.3.Single enantiomer drugs at risk of racemization 
Amongst the few compounds that have been approved as single stereoisomers, but 
which these calculations predict as likely to racemize, some are prodrugs that render 
the racemization less relevant. Others have been tested for racemization in vivo with 
none detected, suggesting that any racemization occurs on a timescale that is longer 
than the compounds are cleared from systemic circulation.  Developing a deeper 
understanding of which properties have allowed these exceptional compounds to make 
it to the market is of obvious interest. 
 
7.4. Quantitative predictions reduce the risks introduced by fallible humans 
It seems clear that drug discovery scientists have been bringing forward compounds for 
clinical testing which have a tendency to racemize without correctly appreciating the 
risk of failure and the extra challenges that such molecules present. This behaviour 
appears to be a typical example of underestimating poorly appreciated risk and 
neglecting under-appreciated opportunities, which also occurs, e.g., in the case of self-
disproportionation of enantiomers.[57-61] The tools that have recently been described 
should help pre-empt and avoid problems in the future and it is our strongly held 
opinion that their use would be a sensible step to take when prioritising a set of 
compounds for synthesis in a drug discovery project. We envisage that tools 
quantitatively predicting racemization risk will find a permanent place in the medicinal 
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chemist’s toolbox alongside other predicted properties, in particular those stemming 
from the use of artificial intelligence. Such quantitative tools will allow the early 
identification of risk, supporting a lean and safe drug development pipeline. 
 
Article Highlights 
 Racemization can seriously affect the efficacy and safety of drugs 
 Racemization risk can be predicted quantitatively and automatically using a 
group-additivity based approach. 
 Success in clinical trials is negatively correlated with increasing racemization 
risk. 
 Evaluation of racemization risk early on in drug development will reduce late-
stage attrition of the drug development pipeline. 
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Table 1. Groups identified by Testa as increasing or decreasing the stability of an 
adjacent stereogenic carbon. From Ref. [9] 
 
Decrease stability Neutral Increase stability 
Ester Alkyl Carboxylate 
Aryl ketone  Sulfate 
Amide   
Hydroxyl   
Amine   
N-linked imine   
Halogens   
Pseudohalogens   
Aromatic groups   
Benzyl groups   
CH2OH   
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Table 2.  Group contributions (in kcal/mol) for a set of substituents selected to 
represent more than 99% of the functional groups found adjacent to stereogenic 
carbon atoms in databases of compounds relevant to medicinal chemistry. Values in 
square brackets correspond to the deprotonated form of the substituent while those in 
curly brackets correspond to the protonated form. 
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CAPTIONS TO FIGURES 
 
Figure 1. Compounds with stereogenic centers and which are described herein. 
 
Figure 2. A) The length of the bars corresponds to the variance attributable to inverting 
the chirality of a molecule and is that which is in excess of experimental variation; 
properties with no bar are those for which no extra variance could be discerned. Data 
is from Ref. [22] B) The D-value estimates the magnitude of the difference between the 
distribution of changes caused by inverting chirality and those for repeat testing.  Bars 
that are solid correspond to those where a statistically significant difference was 
detected. Data is from Ref. [23].  
 
Figure 3. Proposed mechanisms for racemization and related processes. 
 
Figure 4. A) The percentage of compounds in each of four phases of clinical 
development that we compute to have a high likelihood of biologically relevant 
racemization.  B) The proportion of approved drugs that belong to different compound 
types and the proportion belonging to different stereochemical classes for synthetic 
small molecules and natural product derived molecules. C) The number of compounds 
that we compute to have a high likelihood of biologically-relevant racemization that 
were approved in each of the decades shown and whether the compounds are used as 
racemates or single stereoisomers. 
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